- Home
- EWCZ vs MIST Comparison
EWCZ vs MIST Comparison
Compare EWCZ & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | MIST |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 163.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EWCZ | MIST |
|---|---|---|
| Price | $3.62 | $2.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $5.50 | ★ $8.50 |
| AVG Volume (30 Days) | 321.1K | ★ 9.4M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.45 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $211,264,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $14.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.72 | $0.63 |
| 52 Week High | $7.60 | $3.06 |
Technical Indicators
Market Signals| Indicator | EWCZ | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 41.06 |
| Support Level | $3.67 | $2.00 |
| Resistance Level | $3.88 | $2.22 |
| Average True Range (ATR) | 0.17 | 0.32 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 0.74 | 35.28 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).